Verastem (VSTM) Total Current Liabilities (2011 - 2026)
Verastem's (VSTM) quarterly Total Current Liabilities came in at $66.8 million in Q1 2026, up 87.67% year-on-year from $35.6 million in Q1 2025, and down 7.5% quarter-over-quarter from $72.3 million in Q4 2025.
Verastem (VSTM) Total Current Liabilities (2011 - 2026) Analysis & Trends
Verastem's Total Current Liabilities history runs 16 years deep, the most recent figure standing at $66.8 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 87.67% year-over-year to $66.8 million in Q1 2026; TTM through Mar 2026 was $66.8 million, a 87.67% increase from a year earlier, with the FY2025 full-year figure at $72.3 million, up 133.33% from the prior year.
- Total Current Liabilities eased to $66.8 million in Q1 2026 per VSTM's latest filing, from $72.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $72.3 million in Q4 2025 and bottomed at $16.9 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $26.7 million (2024), against an average of $34.4 million.
- Across the five-year window, Total Current Liabilities grew 3.46% in 2023 and jumped 133.33% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $21.7 million in 2022, then advanced by 21.77% to $26.4 million in 2023, then increased by 17.41% to $31.0 million in 2024, then surged by 133.33% to $72.3 million in 2025, then decreased by 7.5% to $66.8 million in 2026.
- Per Business Quant, the three latest VSTM Total Current Liabilities figures stand at $66.8 million (Q1 2026), $72.3 million (Q4 2025), and $59.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Verastem | 166.09 Mn | -31.73 Mn | 15.90 Mn | 66.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.85 Mn |
| Dec 31, 2025 | 72.27 Mn |
| Sep 30, 2025 | 59.71 Mn |
| Jun 30, 2025 | 50.36 Mn |
| Mar 31, 2025 | 35.62 Mn |
| Dec 31, 2024 | 30.97 Mn |
| Sep 30, 2024 | 37.37 Mn |
| Jun 30, 2024 | 30.35 Mn |
| Mar 31, 2024 | 26.73 Mn |
| Dec 31, 2023 | 26.38 Mn |
| Sep 30, 2023 | 23.81 Mn |
| Jun 30, 2023 | 20.79 Mn |
| Mar 31, 2023 | 22.36 Mn |
| Dec 31, 2022 | 21.66 Mn |
| Sep 30, 2022 | 21.87 Mn |
| Jun 30, 2022 | 20.09 Mn |
| Mar 31, 2022 | 16.89 Mn |
| Dec 31, 2021 | 18.59 Mn |
| Sep 30, 2021 | 13.54 Mn |
| Jun 30, 2021 | 12.74 Mn |